Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post Market Study of the 3DKnee™ With E-plus Insert (e-plus)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01551472
Recruitment Status : Recruiting
First Posted : March 12, 2012
Last Update Posted : August 28, 2019
Sponsor:
Collaborator:
DJO Incorporated
Information provided by (Responsible Party):
Encore Medical, L.P.

Tracking Information
First Submitted Date March 8, 2012
First Posted Date March 12, 2012
Last Update Posted Date August 28, 2019
Study Start Date April 2012
Estimated Primary Completion Date June 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 4, 2013)
Efficacy of the Vitamin E UHMWPE as part of the total knee system, measured by Knee Society Score Evaluation and total number of radiologic failures of the device. [ Time Frame: 2 year ]
The (American) Knee Society Score has both an objective and a functional component. The objective score takes into account pain, flexion, stability, alignment, extension lag and flexion contracture. Overall success will be defined as a KSS score ≥ 80 at two years. Radiolucencies have been defined as two types, with one type being more common than the other. In the case of physiologic radiolucency, which is the most common type of radiolucency seen, there is a narrow line present that is well-defined around the prosthesis. This line is surrounded by a radio-dense line and tends to consolidate (disappear) within the first year. The second type of radiolucency, the pathologic radiolucency, is rarer and is associated with loosening and infection. It is a progressive, poorly defined radiolucency that is more than 2 mm thick and without a radiolucent line.
Original Primary Outcome Measures
 (submitted: March 8, 2012)
  • Knee Society Score Evaluation [ Time Frame: 2 year ]
    The (American) Knee Society Score has both an objective and a functional component. The objective score takes into account pain, flexion, stability, alignment, extension lag and flexion contracture and is calculated on a total possible score of 100. The function portion of the KSS, also calculated out of a total of 100 possible points, gives points for walking distance and stair climbing and deducts points for walking aids. Overall success will be defined as a KSS score ≥ 80 at two years.
  • Number of Participants With Radiologic Failure of Device [ Time Frame: 2 year ]
    Radiolucencies have been defined as two types, with one type being more common than the other. In the case of physiologic radiolucency, which is the most common type of radiolucency seen, there is a narrow line present that is well-defined around the prosthesis. This line is surrounded by a radio-dense line and tends to consolidate (disappear) within the first year. The second type of radiolucency, the pathologic radiolucency, is rarer and is associated with loosening and infection. It is a progressive, poorly defined radiolucency that is more than 2 mm thick and without a radiolucent line
Change History Complete list of historical versions of study NCT01551472 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: October 4, 2013)
  • Change in Knee Society Score from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of motion. Grading for KS Score: Excellent (90-100), Good (80-90), Fair (70-79) and Poor (<70).
  • Change in WOMAC Osteoarthritis Index from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Western Ontario McMaster Arthritis Index is a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip. It can be self-administered. It assesses the pain, joint stiffness, physical, social & emotional function of a person with osteoarthritis in determining the overall level of disability.
  • Change in Oxford Knee Score from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Oxford Knee Score (OKS) is a patient-based outcomes measure consisting of 12 questions that is sensitive, simple and validated. It is based on a maximum score of 48.
  • Change in response to Quality of Life questions from pre-surgery to 6 months and each year thereafter through 10 years [ Time Frame: 10 years ]
  • 6. Change in pain from pre-surgery to 6 months and each year thereafter through 10 years [ Time Frame: 10 years ]
Original Secondary Outcome Measures
 (submitted: March 8, 2012)
  • Change in Knee Society Score from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Knee Society Score includes a knee rating and function score. This evaluation covers the knee rating score with three main parameters of pain, stability and range of motion and that flexion contracture, extension lag and misalignment should be dealt with as deductions. Thus, 100 points will be obtained by a well-aligned knee with no pain, 125 degrees of motion, and negligible anteroposterior and mediolateral instability. 50 points are allotted for pain, 25 for stability, and 25 for range of motion. Grading for KS Score: Excellent (90-100), Good (80-90), Fair (70-79) and Poor (<70).
  • Change in WOMAC Osteoarthritis Index from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Western Ontario McMaster Arthritis Index is a set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip. It can be self-administered. It assesses the pain, joint stiffness, physical, social & emotional function of a person with osteoarthritis in determining the overall level of disability.
  • Change in Oxford Knee Score from pre-surgery to 10 years [ Time Frame: 10 year ]
    The Oxford Knee Score (OKS) is a patient-based outcomes measure consisting of 12 questions that is sensitive, simple and validated. It is based on a maximum score of 48.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Post Market Study of the 3DKnee™ With E-plus Insert
Official Title Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus Insert)
Brief Summary The purpose of this study is to evaluate the use and efficacy of the 3DKnee™ System using Vitamin E UHMWPE tibial inserts for total knee replacement surgery.
Detailed Description Total knee replacement surgery is widely accepted as effective treatment for degenerative joint disease (DJD), osteoarthritis and rheumatoid arthritis. Relief of patient pain and return of mobility are the primary goals that can be accomplished by this surgery. Currently available prosthetic designs accomplish these goals and the surgery has been defined as one of the most successful operations available to improve the quality of life for patients with DJD. This study will evaluate subjects who are candidates for a total knee replacement and meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE).
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Subjects must be diagnosed with either osteoarthritis or traumatic arthritis and be candidates for a primary total knee arthroplasty. They must also meet the indications for use for the 3DKnee system with the vitamin E tibial insert.
Condition
  • Degenerative Joint Disease
  • Osteoarthritis
  • Traumatic Arthritis
Intervention Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
Study Groups/Cohorts 3DKnee™ with e-plus Insert
Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
Intervention: Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: March 8, 2012)
300
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 2024
Estimated Primary Completion Date June 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subject must be a candidate for a total primary knee replacement.
  • Subject must have knee joint disease related to degenerative joint disease, including osteoarthritis or traumatic arthritis
  • Subject has a BMI ≤ 40.00 kg/m2
  • Subject is likely to be available for evaluation for the duration of the study
  • Subject is able and willing to sign the informed consent and follow study procedures
  • Subject is not pregnant
  • Subject must be between age 40 and age 75 at the time of consent

Exclusion Criteria:

  • Subject has had a prior total or uni-knee replacement on this knee in the past (no revisions allowed in study)
  • Subject has avascular necrosis of the femoral condyles, post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy, moderate valgus, varus, or flexion deformities or rheumatoid arthritis
  • Subject has an active cancer or is a survivor for <5 years except for squamous cell or basal cell skin cancer
  • Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol
  • Subject is currently a documented substance abuser (alcohol or other addictions)
  • Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic
  • Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity
  • Subject has a BMI > 40.00 kg/m2
  • Subject has loss of ligamentous structures
  • Subject has high levels of physical activity and is unwilling to modify levels of physical activity commensurate with recommendations
  • Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)
  • Subject is a prisoner
  • Subject is pregnant
  • Subject has known materials sensitivity (to metals)
  • Subject is younger than 40 years (<40) or older than 75 years (>75) at the time of consent
Sex/Gender
Sexes Eligible for Study: All
Ages 40 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Beth LG Brakewood, MPH 512-541-6408 beth.brakewood@djoglobal.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01551472
Other Study ID Numbers PS-706
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Encore Medical, L.P.
Study Sponsor Encore Medical, L.P.
Collaborators DJO Incorporated
Investigators Not Provided
PRS Account Encore Medical, L.P.
Verification Date August 2019